Subscribe
gavel-istock-508411976_andreypopov
AndreyPopov / iStockphoto.com
1 November 2017Big Pharma

Eli Lilly defeated as Cialis patent found obvious on appeal

The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Eli Lilly tries to halt another Cialis generic
10 April 2018   Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.
Americas
Eli Lilly considers BMS trademark opposition
21 November 2017   Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb at the US Patent and Trademark Office.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025

More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Eli Lilly tries to halt another Cialis generic
10 April 2018   Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.
Americas
Eli Lilly considers BMS trademark opposition
21 November 2017   Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb at the US Patent and Trademark Office.

More on this story

Big Pharma
UK Supreme Court invalidates Eli Lilly patent relating to Cialis
27 March 2019   The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Americas
Eli Lilly tries to halt another Cialis generic
10 April 2018   Eli Lilly is attempting to stop a Chinese company from manufacturing a generic version of blockbuster drug Cialis.
Americas
Eli Lilly considers BMS trademark opposition
21 November 2017   Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb at the US Patent and Trademark Office.

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud
US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug